Rheumatoid Arthritis eJournal Club
   

Prevention of Infection in Rheumatoid Arthritis
Patients Receiving Biologic Agents

Print this Content
 
Release Date:  February 6, 2009 Renewal Date:  February 8, 2010 Expiration Date:  July 8, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion

1 hour

Description / Overview

The purpose of this activity is to review infection risk and vaccine use in a patient with rheumatoid arthritis (RA) who is under treatment with biologic disease-modifying antirheumatic drugs (DMARDs).
Objectives On completion of this activity, participants should be able to:
  1. Identify the relevant factors for managing infection risk and administration of vaccines in a patient with RA.
  2. Review safety data concerning the use of biologic DMARDs in a patient with RA who is a candidate for vaccination.
  3. Discuss treatment options for a patient with RA who has or will be vaccinated.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty John J. Cush, MD
Professor
Department of Medicine
Division of Rheumatology
Baylor University Medical Center
Clinical Professor, Internal Medicine
Director of Clinical Rheumatology
Baylor Research Institute
The University of Texas Southwestern Medical School at Dallas
Dallas, Texas
Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Leonard H. Calabrese, DO
  Consulting: Abbott Laboratories;
Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
John J. Cush, MD
  Consultant and Advisor: Abbott Laboratories; Centocor, Inc.; Pfizer Inc.; Roche Laboratories, Inc.; UCB; Wyeth Pharmaceuticals
 
  Clinical Investigator: Celgene Corporation; CORRONA; Genentech, Inc.; Pfizer Inc.; Roche Laboratories, Inc.; UCB

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

Bristol – Myers Squibb Company, Genentech/Biogen Idec

Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME.

CME Disclaimer